# Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction

> **NCT05060588** · PHASE4 · UNKNOWN · sponsor: **Qingdao Central Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Myocardial Infarction
- Hypertension

## Interventions

- **DRUG:** Sacubitril/Valsartan 49/51mg/Tab
- **DRUG:** Valsartan 80mg/Tab

## Key facts

- **NCT ID:** NCT05060588
- **Lead sponsor:** Qingdao Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10
- **Primary completion:** 2022-10
- **Final completion:** 2023-02
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2021-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05060588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05060588, "Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05060588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*